New meta-analysis data suggests rethinking transfusion strategies for patients with heart attack & anemia. Restrictive strategies were linked to higher cardiac mortality & lower 6-month survival.
Learn about this research & more in our 2025 Annual Report: thecvc.ca/annual-repor...
Pooled data from the VICTOR & VICTORIA trials demonstrates vericiguat reduces CV death & HF hospitalizations across the HFrEF spectrumโfrom stable to recently worsened cases.
Learn about this research & other highlights in the 2025 CVC Annual Report: thecvc.ca/annual-repor...
We spoke with Justin Ezekowitz, MD, to discuss his recent analysis of the SODIUM-HF trial, which indicated that dietary salt limitations may only benefit patients at the lowest risk for heart failure, contrary to popular belief.
Watch now:
Weโre pleased to share our 2025 Annual Report: The Arteries of Innovation.
Innovation thrives on the circulation of diverse ideas. Discover how the CVC translates high-quality data into clinical solutions bridging the gap from discovery to care.
Read the report hereโก๏ธ: thecvc.ca/annual-repor...
Two graphs compare bleeding with abelacimab vs. rivaroxaban. Graph A: bar graph shows incidence rate per 100 patient-years stratified by age. Graph B: probability of major bleeding vs. age for rivaroxaban and abelacimab pooled dose.
Among older patients with #AtrialFibrillation, abelacimab reduced major or clinically relevant bleeding vs rivaroxaban, with a greater absolute risk reduction in those aged โฅ75 years. bit.ly/4alEy1P
Registration is open for the next webinar in our ASCVD Education Series, taking place Thursday, January 29, 2026, at 8:00 p.m. ET. Join us as experts explore evidenceโbased strategies to enhance patient outcomes and support best practices in ASCVD management.
Register today๐https://bit.ly/3ZynKiT
In this @jamacardiology.com .com viewpoint, Drs. Armstrong, Bainey, & Granger advocate for aligning #STEMI time metrics with current first-point-of-contact capabilities to ensure optimized outcomes for all patients, regardless of geographic location.
jamanetwork.com/journals/jam...
The VICTOR study results complement those of the VICTORIA by extending the evidence base for vericiguat in a contemporary lower-risk, well-treated ambulatory #HFrEF population.
Explore more insights from the VICTOR trial โก๏ธ https://bit.ly/4blPC0O #HeartFailure
The winter issue of the Canadian Cardiac Chronicle Newsletter is now available!
Read more about our current trials, research highlights, & other recent news & updates here: mailchi.mp/bed47c9edc60...
Now accepting applications! The CVC Scholar Program is a unique training opportunity for early-stage investigators focused on cardiovascular disease research.
Learn more & apply โก๏ธ: thecvc.ca/programs-and...
#cardiosky #cardiology
American Society of Nephrology Kidney Week 2025 Original Article | Nov. 7, 2025 | NEJM.org Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis Fig. 1A. A Serious Cardiovascular Events The NEJM identity sits at the bottom.
In the PISCES trial involving participants receiving hemodialysis, fish oil (nโ3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results: nej.md/49zWuqo
@asnkidney.bsky.social | #KidneyWk
Congratulations to CVC Co-Director Dr. Padma Kaul, who has been named Tier 1 Canada Research Chair in Women and Childrenโs Cardio-Metabolic Health. ๐
www.ualberta.ca/en/the-quad/...
In STEMI patients with multivessel disease, reduced LVEF increases ischaemic risk โ but the COMPLETE trial showed complete revascularisation reduces major CV events regardless of LVEF. #cardiosky #medsky #LVEF #cardiology
eurointervention.pcronline.com/article/impa...
๐จ Just published! This guideline provides multi-disciplinary clinical teams with practical recommendations for SGLT2is, MRAs, ARNI and drugs with GLP-1 receptor agonist activity.
Read the guideline here: onlinecjc.ca/article/S082...
#Cardiosky #HeartFailure
At #HFSA2025, we spoke with Justin Ezekowitz, MD, co-director of the Canadian VIGOUR Center, to discuss his analysis of background therapies in the VICTOR trial of vericiguat in HFrEF.
Watch now:
โฃ๏ธThe Fall 2025 issue of the CVC Chronicle newsletter is now availableโฃ๏ธ
Read about our current trials, research highlights, & other recent news/updates here: tinyurl.com/3w4srx67
Women with asthma, particularly active asthma, are at higher risk for preterm birth, low birth weight, & C-section, highlighting the need for improved asthma monitoring & management during pregnancy. @wchriuofa.bsky.social @stollerykids.bsky.social @ualberta.bsky.social
Dr. Moorthy reviewing the WHO global action plan for clinical trial ecosystem strengthening at the 4th Annual ACT meeting in Cape Breton, NS. We are making progress in Canada but lots of work to do!
@cvcualberta.bsky.social @csnscn.bsky.social @ualberta.bsky.social
New analysis published in @jcardfail.bsky.social: applying the 5-STAR risk stratification method to VICTORIA trial data revealed a greater treatment effect for vericiguat on the composite endpoint of CV death or HF hospitalization.
Read more โก๏ธ: authors.elsevier.com/a/1llYy3pkRz...
Happy to have had the chance to contribute to this amazing collaborative work led by @sandeepsahaymd.bsky.social and Dr Ray Benza
Figure highlighting selected opportunities for promotion of CKM health and prevention of heart failure at the individual, health-care system and community, and population and policy levels. CKM=cardiovascular-kidney-metabolic. Copyright: 2025 Elsevier Ltd. All rights reserved.
Heart failure affects more than 55 million people worldwide. ๐ซ
A new Lancet Series, presented at #ESC2025, serves as a call to action for clinicians, health systems, and governments to prioritise the primary prevention of heart failure. tinyurl.com/2sty9386
Late-breaking science from VICTOR & VICTORIA trials presented at #ESCCongress add to growing body of evidence surrounding vericiguat in treating patients with HFrEF. Read more: https://bit.ly/4lTUNXE
#HeartFailure
In #HFrEF, quadruple therapy (ARNi, ฮฒ-blockers, MRA, #SGLT2i) improves survival. Adding #vericiguat may offer a modest ~0.7-year gain, though findings are exploratory, as they are derived from a secondary endpoint of a single trial https://bit.ly/4mE83Rp
#JACC #ESCCongress #WCCardio
The AURORA study is currently recruiting adults & adolescents with type 1 diabetes (T1D) & caregivers for an advisory group. Share your experience navigating the Alberta healthcare system & help us create a vital T1D knowledge hub!
Learn more โก๏ธ: thecvc.ca/aurora-recru...
Excited to finally share our
James Lind Alliance
#Top10 Research Priorities for #LungTransplantation ๐ซ๐ฌ๐ฉ๐ฝโ๐ฌ
@ualberta.bsky.social
@ubcmedicine.bsky.social
@umontreal.ca @uhnresearch.ca @ucalgarymed.bsky.social
www.jhltopen.org/article/S295...
Patients hospitalized with influenza are just as likely as COVID-19 patients to have signs of myocardial involvement. Lead study author Finlay McAlister said the findings show a need to screen and monitor patients more closely. www.tctmd.com/news/cardiac...
New in @jaccjournals.bsky.social: A secondary analysis of the VICTORIA trial investigates the impact of geographic variation and Human Development Index on heart failure outcomes. ๐ซ ๐
Read more here: www.sciencedirect.com/science/arti...
๐ญ Review of transcatheter aortic valve insertion (#TAVI) clinician opinions on the CCS Post-TAVI Driving Guidelines: is a 1-month driving restriction period overly cautious? Read more โฌ๏ธ
cjcopen.ca/article/S258...
#CJCO #OpenAccess
Among patients with opioid-associated out-of-hospital cardiac arrest, chest compression and ventilation CPR was associated with a higher odds of favorable neurologic outcomes at hospital discharge.
ja.ma/4l7We4q
Dr. Jason Weatherald explains how your everyday clinic visits can help shape the future of pulmonary hypertension treatment. @phaware.bsky.social podcast ep 524 @phacanada #phawareMD @teamphhope @albertaphdoc.bsky.social @ualberta.bsky.social medium.com/p/im-aware-t...
